Microcap Ledger Elicio Therapeutics, Inc. $ELTX
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Boston, MA
- Fiscal year end
- December 31
- Shares outstanding
- 26,281,882 [10-Q 2026-08-13]
What the company doesAI summary of filing
Elicio Therapeutics is a clinical-stage biotechnology company developing lymph node-targeted immunotherapies for cancer treatment. The company's lead product candidate, ELI-002 7P, is designed to stimulate immune responses against pancreatic ductal adenocarcinoma and other solid tumors carrying mutant KRAS mutations; it is currently in a Phase 2 clinical trial. The company also has preclinical-stage product candidates ELI-007 targeting BRAF-driven cancers and ELI-008 targeting TP53-expressing cancers. Elicio generates revenue primarily through potential future product sales and currently receives research funding support, but is pre-revenue in terms of marketed products. [10-K 2026-03-12]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$20.04M | −$19.81M | $23.48M | [10-Q 2026-08-13] |
| FY ended Dec 2025 | — | −$39.57M | −$36.95M | $18.56M | [10-K 2026-03-12] |
| FY ended Dec 2024 | — | −$51.90M | −$37.07M | $17.62M | [10-K 2026-03-12] |
- Quarterly cash burn
- −$9.90M
- Cash runway Estimate
- ~7.1 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2025-03-25 | 15,953,524 | [10-K 2025-03-31] |
| 2025-05-09 | 15,996,976 | [10-Q 2025-05-13] |
| 2025-08-05 | 16,338,284 | [10-Q 2025-08-07] |
| 2025-11-10 | 17,489,516 | [10-Q 2025-11-13] |
| 2026-03-10 | 18,396,074 | [10-K 2026-03-12] |
| 2026-04-09 | 18,704,798 | [10-K/A 2026-04-29] |
| 2026-05-08 | 19,086,081 | [10-Q 2026-05-11] |
| 2026-08-11 | 26,281,882 | [10-Q 2026-08-13] |
- Shelf registration
- S-3 filed 2026-02-27; declared effective 2026-03-16 [S-3 2026-02-27]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-09 | DEF 14A | Proxy statement |
| 2026-09-14 | 8-K | Other events |
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-08-13 | 8-K | Results of operations |
| 2026-07-16 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-07-08 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-07-02 | 424B5 | Prospectus or prospectus supplement |
| 2026-07-02 | 8-K | Material agreement entered; Other events |
| 2026-06-24 | 8-K | Regulation FD disclosure |
| 2026-06-17 | 8-K | Other events |
| 2026-06-15 | 8-K | Other events |
| 2026-05-11 | 10-Q | Quarterly report |
Alerts for $ELTX
Email me when Elicio Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.